Approaches to disease modification in MS
The following therapeutic strategies are accepted or are under investigation:
- non-specific immune suppression
- inhibition of interaction between T cell and antigen presenting cell
- interuption of lymphocyte migration into the central nervous system
- alteration of the balance of immune activation away from pro-inflammatory Th1 lymphocytes
- promotion of remyelination
In practise only beta-interferon has been shown to alter the activity of the disease and possibly to reduce disability. Intravenous immunoglobulin and glatitramer acetate are promising alternatives.
Related pages
Create an account to add page annotations
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page